Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data to Continue Biomarker Evaluation for Vilazodone Response

NEW YORK (GenomeWeb News) – Clinical Data said today that the biomarker it had previously associated with response to its depression drug candidate vilazodone did not replicate its earlier success in the firm's most recent phase III study of the drug.

The Newton, Mass.-based drug developer and pharmacogenomic test maker reported positive top-line results from the second of two phase III studies of vilazodone. Clinical Data said that the drug achieved statistically significant results on the primary and secondary endpoints related to major depressive disorder.

Though the biomarker did not meet its goal in the study, Clinical Data said that it would continue to evaluate other biomarker candidates. "While our lead biomarker of response to vilazodone did not replicate in this trial, it is one in a series of candidate biomarkers that we will continue to evaluate," Carol Reed, chief medical officer of Clinical Data, said in a statement.

Clinical Data said that it intends to submit the data from the most recent study to the US Food and Drug Administration in support of its marketing application of vilazodone by the end of this year.

In Tuesday afternoon trade on the Nasdaq, shares of Clinical Data were up around 3 percent at $14.48.

Filed under

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.